Samsung Medical Center
| Corea del Sud | Turchia | Austria | |
| Trapianto di midollo osseo allogenico da donatore non correlato | da $145,000 | da $80,000 | da $180,000 |
| Trapianto di midollo osseo allogenico da donatore consanguineo | da $75,000 | da $65,000 | da $150,000 |
| Trapianto di midollo osseo | da $55,000 | da $36,000 | da $140,000 |
| Trapianto autologo di midollo osseo | da $42,000 | da $31,500 | da $50,000 |
| Chemioterapia per carcinoma mammario | da $19,200 | da $1,200 | da $15,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Linfoma non-Hodgkin. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Linfoma non-Hodgkin e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Linfoma non-Hodgkin.
Il medico dirige la Divisione di Ematologia-Oncologia e si è laureato presso il College of Medicine dell'Università Nazionale di Seoul.<\/p>
È specializzato in cancro ai polmoni, cancro alla testa e al collo e cancro esofageo. È membro di diverse organizzazioni prestigiose, tra cui l'Associazione Medica Coreana, l'American Society of Clinical Oncology e l'European Society of Medical Oncology.<\/p>
Il medico è un ematologo-oncologo altamente esperto con oltre 26 anni di esperienza nel campo. Specializzato nel trattamento del cancro del colon, dell'oncologia ematologica, dei mielomi e dei linfomi, il medico è competente in procedure avanzate come il trapianto di midollo osseo, inclusi i trapianti da donatori alternativi e non compatibili.<\/p>
Con un forte background accademico, il medico possiede un M.D. dal College of Medicine dell'Università Yonsei e un Ph.D. dal College of Medicine dell'Università Sungkyunkwan. Il medico è anche membro di numerose società professionali e ha contribuito al campo attraverso numerose pubblicazioni di articoli.<\/p>
Il dottore è un esperto in chirurgia oncoplastica e cancro al seno, con una vasta esperienza in istituzioni prestigiose. Il dottore possiede una laurea in medicina (M.D.) dal College of Medicine della Seoul National University e un master in chirurgia (M.S.) dalla stessa istituzione. Inoltre, il dottore ha conseguito una laurea in scienze biologiche (B.S.) presso il Korea Advanced Institute of Science and Technology (KAIST) e un dottorato di ricerca (Ph.D.) in chirurgia presso la Graduate School della Seoul National University.<\/p>
South Korea reports high Non-Hodgkin lymphoma success rates with a 10-year survival of nearly 79.2% at top institutions. Major Seoul hospitals achieve 85% to 90% remission for early-stage cases. Advanced protocols like R-CHOP show an 84.2% complete remission rate for diffuse large B-cell lymphoma.
Bookimed Expert Insight: Clinical volume is the strongest indicator of success for complex blood cancers in Korea. Leading centers like Samsung Medical Center serve over 2 million patients yearly. This massive scale allows doctors to maintain specialized proficiency in rare lymphoma subtypes that smaller facilities rarely treat.
Patient Consensus: Patients value the rapid diagnostic speed in Seoul, where biopsy reviews and imaging often finish in days. Many note that choosing a major university hospital is vital for accessing the latest specialized hematology teams.
Korean tertiary hospitals actively use modern CAR-T cell therapy for relapsed or refractory Non-Hodgkin lymphoma. Specialized facilities like Samsung Medical Center and Asan Medical Center provide these personalized treatments. These centers utilize commercial therapies like Kymriah for patients with limited options.
Bookimed Expert Insight: While several Korean hospitals hold JCI or KOIHA accreditation, CAR-T therapy requires unique infrastructure. Asan Medical Center and Severance Hospital manage massive patient volumes, with Severance seeing 1.6 million outpatients annually. This high volume allows these teams to maintain specialized cells labs required for complex CAR-T processing. When choosing a facility, confirm they handle the entire process from cell collection to toxicity monitoring in-house.
Patient Consensus: Patients note that major hospitals in Seoul organize workups very quickly compared to other countries. They emphasize that this therapy is usually a last-line option after standard chemotherapy or transplants fail.
Samsung Medical Center, Seoul National University Hospital, and Asan Medical Center are leading facilities for Non-Hodgkin lymphoma treatment in South Korea. These centers hold JCI and KOIHA accreditations. They offer advanced therapies like allogeneic bone marrow transplantation and specialized oncology care in Seoul.
Bookimed Expert Insight: Samsung Medical Center and Asan Medical Center consistently handle the highest surgical and patient volumes in Korea. Samsung manages over 45,000 operations annually. Asan performs over 65,000 yearly. This massive volume ensures their oncology teams have deep experience in rare lymphoma subtypes.
Patient Consensus: Patients note it is essential to bring original pathology slides and imaging to Seoul for re-review. Selecting a center with dedicated English-language coordination simplifies the complex treatment process.
Treatment for non-Hodgkin's lymphoma in South Korea typically begins within 1 to 2 weeks after diagnostics are complete. Specialists at major Seoul centers prioritize aggressive cases. Therapy starts after bone marrow punctures, PET-CT scans, and pathology reviews finalize the specific lymphoma subtype and staging.
Bookimed Expert Insight: While patients often focus on the treatment start date, our data shows the most critical time-saver is choosing a digital-integrated hospital. Seoul National University Bundang Hospital uses the BESTcare system to sync pathology and imaging instantly. This connectivity often shaves 3 days off the pre-treatment wait compared to manual data transfers.
Patient Consensus: Patients note that major university hospitals in Seoul provide the fastest path to treatment. They emphasize that the real wait occurs during pathology review and suggest having a single coordinator to sync different tests.
Most oncohematologists in major South Korean tertiary hospitals speak functional English. These specialists utilize English for medical research and global conferences. Large Seoul-based centers like Samsung Medical Center and Severance Hospital maintain dedicated international departments to ensure clear communication during complex lymphoma treatments.
Bookimed Expert Insight: While South Korea ranks 4th globally for patient requests, our data shows a concentration of English proficiency in major university hospitals. Centers like Asan Medical Center handle over 182,000 patients annually and prioritize international services. Choosing a hospital with JCI or GHA accreditation ensures a structured communication framework for international oncology patients.
Patient Consensus: Patients note that while doctors understand technical medical terms well, administrative staff might not. They highly recommend using hospital-provided interpreters and bringing all previous pathology reports in English to avoid misunderstandings.